Overview

Price chart · mood · technical indicators

GILD

Gilead Sciences Incstock Healthcare

Drug Manufacturers - General

$132.6935.56%Current Market Mood:Neutral

Market Mood

Price Range (1Y)

$95.30$157.27

Current: $132.69

Idea: EMA

1Y Return

+12.2%

Sharpe 3Y

0.70

Market Comparison

vs Healthcare Sector & Drug Manufacturers - General Industry

GILD

+35.56%

1Y Performance

Healthcare

Sector 1Y

Drug Manufacturers - General

Industry 1Y

Fundamentals

Updated daily after market close

P/E ratio19.42Forward 15.06

EPS (TTM)$6.7823.4% YoY

Profit margin28.9%HEALTHCARE

Market cap$163.40BLarge cap

Wall Street coverage

$158.36median target· current $65.54 (+141.6%)30 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E: 15.06
PEG ratio: 0.37
P/B: 7.20
P/S (TTM): 5.55
EV/EBITDA: 13.16

Profitability & growth

ROE (TTM): 40.7%
Operating margin: 37.4%
Revenue growth YoY: 4.7%
Dividend yield: 2.4%
Beta: 0.40

Last earnings

Apr 23, 2026 · Estimate $1.89 · Reported $0.00

Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

50 articles · sorted by date

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About Gilead Sciences Inc

Company profile

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

Classification

Sector: Healthcare
Industry: Drug Manufacturers - General
Exchange: NASDAQ
Country: USA
Currency: USD

Company profile

HQ: 333 LAKESIDE DRIVE, FOSTER CITY, CA
Fiscal year end: December
Latest quarter: Dec 31, 2025

Market cap$163.40B

Shares outstanding$1.24B

52W high$156.40

52W low$92.83

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer

Overview

GILD

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Rising Institutional Interest and Brinsupri Focus Might Change The Case For Investing In Insmed (INSM)

Gilead Shareholders Back Board, Pay Plans at 2026 Meeting

Gilead Sciences Completes Acquisition of Arcellx to Strengthen Oncology Portfolio

Nasdaq 100 Analysis: Palo Alto Networks and DexCom Show Potential, Gilead Sciences Lags - News and Statistics

Varma Mutual Pension Insurance Co Cuts Stock Position in Gilead Sciences, Inc. $GILD

Gilead Sciences to Acquire Tubulis to Advance Targeted Cancer Therapies

Gilead Sciences, Inc. $GILD Shares Bought by Triasima Portfolio Management inc.

Intact Investment Management Inc. Has $10.36 Million Holdings in Gilead Sciences, Inc. $GILD

Compugen sets May 18 earnings release, 8:30 AM ET webcast

Olema Adds Deal Veteran Prakash Raman To Guide Oncology Partnerships

Is Trial Failures And Gilead Pullback Altering The Investment Case For Arcus Biosciences (RCUS)?

Hussman Strategic Advisors Inc. Acquires Shares of 8,400 Amgen Inc. $AMGN

Benjamin Edwards Inc. Has $16.60 Million Holdings in Gilead Sciences, Inc. $GILD

FDA Priority Review For New HIV Combo Might Change The Case For Investing In Gilead Sciences (GILD)

Strs Ohio Reduces Stock Holdings in Gilead Sciences, Inc. $GILD

PFA Pension Forsikringsaktieselskab Purchases Shares of 826,930 Gilead Sciences, Inc. $GILD

Robertson Stephens Wealth Management LLC Has $6.27 Million Stake in Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD Stock Holdings Increased by Sigma Planning Corp

Is It Too Late To Consider Centessa Pharmaceuticals (CNTA) After Its 192% One-Year Surge?

Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wall Street Zen

About Gilead Sciences Inc

Classification

Company profile

GILD

Market Comparison

GILD Market Analysis

Overview

GILD

Market Comparison

Fundamentals

Wall Street coverage

Valuation

Profitability & growth

News & Sentiment

Rising Institutional Interest and Brinsupri Focus Might Change The Case For Investing In Insmed (INSM)

Gilead Shareholders Back Board, Pay Plans at 2026 Meeting

Gilead Sciences Completes Acquisition of Arcellx to Strengthen Oncology Portfolio

Nasdaq 100 Analysis: Palo Alto Networks and DexCom Show Potential, Gilead Sciences Lags - News and Statistics

Varma Mutual Pension Insurance Co Cuts Stock Position in Gilead Sciences, Inc. $GILD

Gilead Sciences to Acquire Tubulis to Advance Targeted Cancer Therapies

Gilead Sciences, Inc. $GILD Shares Bought by Triasima Portfolio Management inc.

Intact Investment Management Inc. Has $10.36 Million Holdings in Gilead Sciences, Inc. $GILD

Compugen sets May 18 earnings release, 8:30 AM ET webcast

Olema Adds Deal Veteran Prakash Raman To Guide Oncology Partnerships

Is Trial Failures And Gilead Pullback Altering The Investment Case For Arcus Biosciences (RCUS)?

Hussman Strategic Advisors Inc. Acquires Shares of 8,400 Amgen Inc. $AMGN

Benjamin Edwards Inc. Has $16.60 Million Holdings in Gilead Sciences, Inc. $GILD

FDA Priority Review For New HIV Combo Might Change The Case For Investing In Gilead Sciences (GILD)

Strs Ohio Reduces Stock Holdings in Gilead Sciences, Inc. $GILD

PFA Pension Forsikringsaktieselskab Purchases Shares of 826,930 Gilead Sciences, Inc. $GILD

Robertson Stephens Wealth Management LLC Has $6.27 Million Stake in Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD Stock Holdings Increased by Sigma Planning Corp

Is It Too Late To Consider Centessa Pharmaceuticals (CNTA) After Its 192% One-Year Surge?

Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wall Street Zen

About Gilead Sciences Inc

Classification

Company profile

GILD

Market Comparison